Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

Table 6 Change in clinical and functional status between baseline and one year by APR levels among biologic-naïve patients

	Neither APR elevated	APR levels discordant	Both APR elevated	P value
	n = 1,012	n = 487	n = 324
mHAQ	0.00 ± 0.29	-0.06 ± 0.35	-0.14 ± 0.41	<0.0001
CDAI	-2.91 ± 10.92	-4.93 ± 12.35	-8.16 ± 13.53	<0.0001
Tender joints	-0.91 ± 5.54	-1.69 ± 5.88	-2.82 ± 6.64	<0.0001
Swollen joints	-1.28 ± 5.11	-1.85 ± 5.60	-2.81 ± 5.78	<0.0001
Patient global assessment	-2.14 ± 26.41	-6.00 ± 27.96	-10.58 ± 30.18	<0.0001
MD global assessment	-5.23 ± 16.46	-7.62 ± 19.49	-14.62 ± 22.91	<0.0001

APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.

ISSN: 1478-6362